Clinical Trials Browser

Phase 1/2 × INDUSTRY × etaracizumab × Clear all

NCT00284817 2008-05-29

Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer

Phase 1/2 Completed

Neoplasms